Information Provided By: 
Fly News Breaks for February 23, 2017
TXMD
Feb 23, 2017 | 15:24 EDT
Following TherapeuticsMD's quarterly report, Guggenheim analyst Louise Chen said she expects Yuvvexy to receive approval on its PDUFA date in May and believes that drug, as well as TX-001HR, have blockbuster potential that is being underappreciated. Together, these drugs target a "multibillion-dollar market opportunity," said Chen, who has a Buy rating and $33 price target on TherapeuticsMD shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
